These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 2841895)

  • 41. [Neuroendocrine carcinoma of cervix: a clinicopathologic study of 82 cases].
    Feng M; Zou J; Zhang Y; Sun L
    Zhonghua Bing Li Xue Za Zhi; 2018 May; 47(5):328-333. PubMed ID: 29783797
    [No Abstract]   [Full Text] [Related]  

  • 42. Lung carcinoma metastatic to the ovary: a clinicopathologic study of 32 cases emphasizing their morphologic spectrum and problems in differential diagnosis.
    Irving JA; Young RH
    Am J Surg Pathol; 2005 Aug; 29(8):997-1006. PubMed ID: 16006793
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Carcinoma of unknown primary site.
    Greco FA; Burris HA; Erland JB; Gray JR; Kalman LA; Schreeder MT; Hainsworth JD
    Cancer; 2000 Dec; 89(12):2655-60. PubMed ID: 11135228
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Atypical carcinoid of the uterine cervix accompanying adenocarcinoma in situ.
    Ling C; Shen Y
    J Clin Pathol; 2018 Nov; 71(11):1030. PubMed ID: 30154130
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A Practical Approach to the Classification of WHO Grade 3 (G3) Well-differentiated Neuroendocrine Tumor (WD-NET) and Poorly Differentiated Neuroendocrine Carcinoma (PD-NEC) of the Pancreas.
    Tang LH; Basturk O; Sue JJ; Klimstra DS
    Am J Surg Pathol; 2016 Sep; 40(9):1192-202. PubMed ID: 27259015
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Cancers of unknown origin: 311 cases].
    Lortholary A; Abadie-Lacourtoisie S; Guérin O; Mege M; Rauglaudre GD; Gamelin E
    Bull Cancer; 2001 Jun; 88(6):619-27. PubMed ID: 11459709
    [TBL] [Abstract][Full Text] [Related]  

  • 47. From Krukenberg to today: the ever present problems posed by metastatic tumors in the ovary. Part II.
    Young RH
    Adv Anat Pathol; 2007 May; 14(3):149-77. PubMed ID: 17452813
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cisplatin and etoposide as first-line chemotherapy for poorly differentiated neuroendocrine carcinoma of the hepatobiliary tract and pancreas.
    Iwasa S; Morizane C; Okusaka T; Ueno H; Ikeda M; Kondo S; Tanaka T; Nakachi K; Mitsunaga S; Kojima Y; Hagihara A; Hiraoka N
    Jpn J Clin Oncol; 2010 Apr; 40(4):313-8. PubMed ID: 20047862
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The biological implications of bronchial tumors.
    Warren WH; Memoli VA; Kittle CF; Jensik RJ; Faber LP; Gould VE
    J Thorac Cardiovasc Surg; 1984 Feb; 87(2):274-82. PubMed ID: 6319828
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Carcinoma of unknown primary site: treatment with 1-hour paclitaxel, carboplatin, and extended-schedule etoposide.
    Hainsworth JD; Erland JB; Kalman LA; Schreeder MT; Greco FA
    J Clin Oncol; 1997 Jun; 15(6):2385-93. PubMed ID: 9196154
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms.
    Moertel CG; Kvols LK; O'Connell MJ; Rubin J
    Cancer; 1991 Jul; 68(2):227-32. PubMed ID: 1712661
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Poorly differentiated carcinoma of unknown primary site: correlation of light microscopic findings with response to cisplatin-based combination chemotherapy.
    Hainsworth JD; Wright EP; Gray GF; Greco FA
    J Clin Oncol; 1987 Aug; 5(8):1275-80. PubMed ID: 2442318
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Renal Cell Carcinoma Presenting as Carcinoma of Unknown Primary Site: Recognition of a Treatable Patient Subset.
    Greco FA; Hainsworth JD
    Clin Genitourin Cancer; 2018 Aug; 16(4):e893-e898. PubMed ID: 29610002
    [TBL] [Abstract][Full Text] [Related]  

  • 54. CUP Syndrome in Neuroendocrine Neoplasia: Analysis of Risk Factors and Impact of Surgical Intervention.
    Begum N; Wellner U; Thorns C; Brabant G; Hoffmann M; Bürk CG; Lehnert H; Keck T
    World J Surg; 2015 Jun; 39(6):1443-51. PubMed ID: 25665670
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Long-term remission in a patient with carcinoma of unknown primary site.
    Jentsch-Ullrich K; Kalinski T; Roessner A; Franke A; Mohren M
    Chemotherapy; 2006; 52(1):12-5. PubMed ID: 16340191
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Tumors of unknown origin.
    Greco FA; Hainsworth JD
    CA Cancer J Clin; 1992; 42(2):96-115. PubMed ID: 1540854
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Carcinoma of unknown primary with gastrointestinal profile: immunohistochemistry and survival data for this favorable subset.
    Varadhachary GR; Karanth S; Qiao W; Carlson HR; Raber MN; Hainsworth JD; Greco FA
    Int J Clin Oncol; 2014; 19(3):479-84. PubMed ID: 23813044
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Metastatic adeno or undifferentiated carcinoma from an unknown primary site--natural history and guidelines for identification of treatable subsets.
    Kirsten F; Chi CH; Leary JA; Ng AB; Hedley DW; Tattersall MH
    Q J Med; 1987 Feb; 62(238):143-61. PubMed ID: 3659256
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Treatment and outcome of cervical lymph nodal metastases of unknown primary sites].
    Yin Y; Tang P; Xu G
    Zhonghua Zhong Liu Za Zhi; 1999 May; 21(3):230-2. PubMed ID: 11776845
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cancer of unknown primary site: review of consecutive cases at the National Cancer Center Hospital of Japan.
    Yakushiji S; Ando M; Yonemori K; Kohno T; Shimizu C; Katsumata N; Fujiwara Y
    Int J Clin Oncol; 2006 Dec; 11(6):421-5. PubMed ID: 17180509
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.